Document is current

Article History

Received: 14 March 2024

Accepted: 20 October 2025

First Online: 26 November 2025

Competing interests

: R.M.K. received honoraria from Stemline. C.K. is an employee of AbbVie Deutschland GmbH & Co. KG. T.H.B. served as a consultant or invited speaker for Astra-Zeneca, Gilead, Janssen, Merck, Novartis and Pfizer and received research funding from Novartis and Pfizer. SK reports research grant/funding from Geron, Janssen, AOP Pharma, and Novartis; consulting fees from Pfizer, Incyte, Ariad, Novartis, AOP Pharma, Bristol Myers Squibb, Celgene, Geron, Janssen, CTI BioPharma, Roche, Bayer, GSK, Sierra Oncology, and PharmaEssentia; payment or honoraria from Novartis, BMS/Celgene, Pfizer; travel/accommodation support from Alexion, Novartis, Bristol Myers Squibb, Incyte, AOP Pharma, CTI BioPharma, Pfizer, Celgene, Janssen, Geron, Roche, AbbVie, GSK, Sierra Oncology, and Karthos; a patent issued for a BET inhibitor at RWTH Aachen University; advisory board activity for from Pfizer, Incyte, Ariad, Novartis, AOP Pharma, BMS, Celgene, Geron, Janssen, CTI BioPharma, Roche, Bayer, GSK, Sierra Oncology, and PharmaEssentia. MG reports speaker bureau and consultancy for AOP Orphan, Celgene, CTI, Novartis, and Shire. I.G. received funding from aTyr. E.L. is co-founder and consultant to IFM Therapeutics, Odyssey Therapeutics and a Stealth Biotech company. D.W. served as a consultant or invited speaker for Novartis, Roche, BMS, Gilead, Janssen, MSD, AOP Orphan and Pfizer and received research funding from Novartis, BMS, AOP Orphan and Pfizer. L.L.T. reports honoraria from AOP Orphan, Boehringer Ingelheim, BMS and Novartis; consultancy for Astellas, Blueprint, BMS, GSK, Jazz Pharmaceuticals, Pfizer, and Sobi. The remaining authors declare no competing financial interests.